

## Rituximab

S

### Failed to develop anti-SARS-Cov-2 antibodies: case report

In a prospective longitudinal observational study involving 45 patients presented to hospital in Italy, one patient [*age and sex not stated*] was described, who failed to develop anti-SARS-Cov-2 antibodies during treatment with rituximab for chronic lymphoproliferative disorders.

The patient had chronic lymphoproliferative disorders. The patient had been receiving rituximab [*route and dosage not stated*]. Subsequently, the patient failed to develop anti-SARS-Cov-2 antibodies [*duration of treatment to reaction onset and outcome not stated*].

Cattaneo C, et al. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. *Blood Cancer Journal* 11 (Suppl.): 14 Sep 2021. Available from: URL: <http://doi.org/10.1038/s41408-021-00546-9> 803614230